GenSight CEO Sees Bright Future After Therapy Gave Blind Man Partial Sight
GS030’s Development Will Now Get Higher Priority
French biotech GenSight will prioritize its optogenetic GS030 treatment after the combination showed breakthrough results in a form of blindness, its CEO tells Scrip.
You may also be interested in...
The Basel-based major has swooped to buy fellow Swiss group Arctos in the belief that optogenetics is a promising therapeutic approach that might restore sight to patients who are legally blind.
The company aims to overcome drawbacks of existing gene therapy platforms, starting in ocular and CNS diseases.
French biotech GenSight Biologics reports top-line results from the Phase III REFLECT study, backing the efficacy of its lead gene therapy in a devastating eye disease, and prepares plans to commercialize the product.